
Define rare diseases and summarize their global epidemiology and impact on clinical trial design. Emphasize registries, the Orphan Drug Act, and patient engagement as drivers of rare disease research.
Navigate the challenges of trial design and recruitment in rare diseases with small populations. Apply adaptive designs, Bayesian methods, and decentralized, patient-centric approaches to boost retention.
Explore innovative trial designs, including single arm, adaptive, and N of one, tailored for rare diseases, enabling ethical, flexible, and efficient research when traditional trials aren’t feasible.
Navigate the regulatory framework for rare disease trials, including the Orphan Drug Act incentives and expedited pathways, with emphasis on ethical considerations and informed consent.
This course is designed to address the unique challenges faced when conducting clinical trials for rare diseases, which affect a small percentage of the population but have a significant impact worldwide. Participants will learn how to navigate these complexities and develop strategies to overcome the barriers in rare disease research.
The course begins with an exploration of the definition and epidemiology of rare diseases, including criteria used globally to define these conditions and their prevalence. The importance of patient registries, such as Orphanet, in providing data for research will be discussed.
Participants will then tackle the challenges in clinical trial design and patient recruitment. Due to small patient populations and geographical dispersion, rare disease trials require innovative strategies to ensure robust trial designs and adequate patient recruitment and retention.
The course emphasizes the use of innovative trial designs that are particularly suited for rare diseases, such as single-arm trials, adaptive designs, and N-of-1 trials, which offer flexibility and personalization to overcome the limitations of traditional trial structures.
A key focus is on collaboration with patient associations, highlighting the importance of patient advocacy groups in recruitment, engagement, and incorporating patient perspectives into research. Effective partnership strategies will also be covered.
Lastly, participants will gain a comprehensive understanding of regulatory and ethical guidelines governing rare disease trials, such as the Orphan Drug Act, and will learn to navigate the regulatory landscape to expedite trial approvals while ensuring ethical treatment of participants.
This course is ideal for clinical researchers, healthcare professionals, and regulatory specialists involved in rare disease trials.